Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.43 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101326 | 0.88 | PIK3CA (0.49) | AKT1PIK3CDPIK3CBPIK3CAEPHX2 | |
| SCHEMBL969480 | 0.87 | AKT1 (0.53) | AKT1PIK3CDPIK3CBPIK3CACYP3A4 | |
| SCHEMBL30794797 | 0.86 | KDM4E (0.53) | AKT1PIK3CDPIK3CBPIK3CAKCNQ2 | |
| SCHEMBL3109034 | 0.86 | KDM4E (0.53) | AKT1PIK3CDPIK3CBPIK3CAKCNQ2 | |
| SCHEMBL2435553 | 0.83 | GPR183 (0.56) | AKT1PIK3CDPIK3CBPIK3CAEPHX2 | |
| SCHEMBL2432710 | 0.77 | GPR183 (0.50) | AKT1PIK3CDPIK3CBPIK3CAEPHX2 | |
| SCHEMBL30795263 | 0.77 | GPR183 (0.50) | AKT1PIK3CDPIK3CBPIK3CAEPHX2 | |
| SCHEMBL2435168 | 0.77 | MAPT (0.57) | AKT1PIK3CDPIK3CBPIK3CAEPHX2 | |
| SCHEMBL30795653 | 0.77 | MAPT (0.57) | AKT1PIK3CDPIK3CBPIK3CAEPHX2 | |
| SCHEMBL30824698 | 0.76 | PIK3CD (0.54) | AKT1PIK3CDPIK3CBPIK3CACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-7683058-B2 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2010-03-23 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | claimed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | claimed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066612-A1 | Substituted pyrimidine derivatives | DPYD, TYMP, TYMS | AKT1 3712/4885PIK3CD 1250/4885PIK3CB 1200/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | AKT1 4605/4885PIK3CD 1397/4885PIK3CB 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.